Lombard Medical Inc. a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), announced the acquisition of Silicon Valley-based Altura Medical.

Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement allowing Corindus to offer the RaySafe i2 real-time radiation dose monitoring system in conjunction with the CorPath System.

Loyola University Medical Center is the first center in Illinois to implant the CoreValve Evolut R percutaneous aortic heart valve that does not require open heart surgery.

Women and black patients lost more years of their expected life after a heart attack when compared to white men, according to a study published in the Journal of the American College of Cardiology.

Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a prospective, randomized, multi-center, controlled study evaluating the safety and efficacy of the C-Pulse system for the treatment of New York Heart Association (NYHA) Class III and ambulatory Class IV heart failure. The study was temporarily paused this past March after the company notified the U.S. Food and Drug Administration (FDA) of four deaths in the treatment arm of the study. The deaths were adjudicated as not device- or therapy-related, and as previously announced on May 26th, the FDA approved resumption of patient enrollment in the study.

Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) expanding indication for QuadraSphere Microspheres to include the embolization of hepatoma.

Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to assess the CONTINUation of Existing risk of ventricular arrhythmias after CRT-D replacement). BioCONTINUE is the first study to investigate the relevance of defibrillator back-up following first device replacement in a heart failure (HF) patient population with a primary indication for a cardiac resynchronization therapy defibrillator (CRT-D).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now